Ifetroban Sodium
Phase 2Small molecule
Ifetroban Sodium is one of 55 small molecule programs targeting Malignant Solid Tumors. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Idiopathic Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Esbriet
LLegacy Health System
Approved
Medrol
PfizerApproved
Viagra
VViatris Specialty LLC
Approved
Remodulin
United TherapeuticsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ifetroban Sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCumberland Pharmaceuticals